## Abstract Prostate cancer (PC) mortality is the most valid endβpoint in screening trials, but could be influenced by the choice of initial treatment if treatment has an effect on mortality. In this study, PC treatment was compared between the screening and control arms in a screening trial. Data
The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?
β Scribed by A. Auvinen; J. Hugosson
- Book ID
- 109050829
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 56 KB
- Volume
- 92
- Category
- Article
- ISSN
- 1464-4096
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract From 1992β2001, 7 countries in Europe gradually recruited men for the European Randomised Screening for Prostate Cancer (ERSPC) trial. Centres recruit different age groups and have different designs for recruiting and countries have different underlying risks for prostate cancer. Recrui
## Abstract Two largeβscale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mo